|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGFN1 |
Gene summary for IGFN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGFN1 | Gene ID | 91156 |
| Gene name | immunoglobulin like and fibronectin type III domain containing 1 | |
| Gene Alias | EEF1A2BP1 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q86VF2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91156 | IGFN1 | PTC01 | Human | Thyroid | PTC | 7.13e-05 | 6.12e-02 | 0.1899 |
| 91156 | IGFN1 | PTC05 | Human | Thyroid | PTC | 8.79e-33 | 2.36e+00 | 0.2065 |
| 91156 | IGFN1 | PTC06 | Human | Thyroid | PTC | 1.43e-21 | 1.11e+00 | 0.2057 |
| 91156 | IGFN1 | ATC09 | Human | Thyroid | ATC | 4.63e-07 | 3.39e-01 | 0.2871 |
| 91156 | IGFN1 | ATC1 | Human | Thyroid | ATC | 3.84e-05 | 3.42e-01 | 0.2878 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Esophagus | ESCC |  |
| Skin | AK |  |
| Skin | SCCIS |  |
| Skin | cSCC |  |
| Thyroid | HT |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
| GO:00508089 | Thyroid | PTC | synapse organization | 161/5968 | 426/18723 | 5.11e-03 | 2.36e-02 | 161 |
| GO:003432924 | Thyroid | ATC | cell junction assembly | 187/6293 | 420/18723 | 1.71e-06 | 2.08e-05 | 187 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGFN1 | SNV | Missense_Mutation | novel | c.4408N>T | p.Met1470Leu | p.M1470L | Q86VF2 | protein_coding | tolerated_low_confidence(0.49) | benign(0.019) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| IGFN1 | SNV | Missense_Mutation | c.9032N>A | p.Leu3011Gln | p.L3011Q | Q86VF2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| IGFN1 | SNV | Missense_Mutation | rs757869019 | c.3595G>A | p.Ala1199Thr | p.A1199T | Q86VF2 | protein_coding | tolerated(0.12) | possibly_damaging(0.691) | TCGA-A2-A0CK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
| IGFN1 | SNV | Missense_Mutation | novel | c.2332N>T | p.Pro778Ser | p.P778S | Q86VF2 | protein_coding | tolerated(0.11) | unknown(0) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| IGFN1 | SNV | Missense_Mutation | c.10990G>A | p.Asp3664Asn | p.D3664N | Q86VF2 | protein_coding | tolerated(0.35) | benign(0.375) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| IGFN1 | SNV | Missense_Mutation | novel | c.5225N>G | p.Asn1742Ser | p.N1742S | Q86VF2 | protein_coding | tolerated_low_confidence(0.12) | unknown(0) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| IGFN1 | SNV | Missense_Mutation | novel | c.8372C>A | p.Pro2791His | p.P2791H | Q86VF2 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IGFN1 | SNV | Missense_Mutation | c.7643G>T | p.Gly2548Val | p.G2548V | Q86VF2 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| IGFN1 | SNV | Missense_Mutation | rs577651874 | c.440N>A | p.Arg147Gln | p.R147Q | Q86VF2 | protein_coding | deleterious(0) | unknown(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| IGFN1 | SNV | Missense_Mutation | c.9358N>A | p.Leu3120Ile | p.L3120I | Q86VF2 | protein_coding | tolerated(0.14) | possibly_damaging(0.672) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |